Aduro BioTech (NASDAQ:ADRO) has been assigned a $10.00 price target by investment analysts at HC Wainwright in a report released on Tuesday. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 39.86% from the stock’s previous close.
A number of other equities analysts have also recently issued reports on ADRO. Oppenheimer began coverage on Aduro BioTech in a report on Monday, October 30th. They issued a “buy” rating and a $15.00 price objective for the company. BidaskClub cut Aduro BioTech from a “hold” rating to a “sell” rating in a report on Saturday, December 9th. William Blair reaffirmed an “outperform” rating on shares of Aduro BioTech in a research report on Monday, October 2nd. Finally, Canaccord Genuity set a $30.00 price target on Aduro BioTech and gave the company a “buy” rating in a research report on Thursday, December 14th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $17.71.
Aduro BioTech (ADRO) traded down $0.05 during mid-day trading on Tuesday, reaching $7.15. The company’s stock had a trading volume of 329,200 shares, compared to its average volume of 389,967. Aduro BioTech has a twelve month low of $6.01 and a twelve month high of $14.05. The stock has a market capitalization of $552.72, a PE ratio of -5.26 and a beta of 3.52.
Aduro BioTech (NASDAQ:ADRO) last released its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.03). Aduro BioTech had a negative net margin of 548.92% and a negative return on equity of 39.28%. The company had revenue of $3.79 million for the quarter, compared to the consensus estimate of $4.04 million. During the same quarter in the previous year, the firm posted ($0.54) earnings per share. The business’s revenue for the quarter was up .0% compared to the same quarter last year. equities analysts predict that Aduro BioTech will post -1.28 earnings per share for the current year.
In related news, insider Stephen T. Isaacs sold 20,200 shares of Aduro BioTech stock in a transaction dated Tuesday, November 7th. The stock was sold at an average price of $7.98, for a total value of $161,196.00. Following the completion of the transaction, the insider now owns 190,321 shares in the company, valued at $1,518,761.58. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Dirk G. Brockstedt sold 4,123 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $8.04, for a total value of $33,148.92. Following the transaction, the executive vice president now owns 77,841 shares of the company’s stock, valued at approximately $625,841.64. The disclosure for this sale can be found here. Insiders sold 267,714 shares of company stock worth $2,251,452 over the last ninety days. Insiders own 6.60% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in ADRO. Harvard Management Co. Inc. bought a new position in Aduro BioTech in the third quarter worth approximately $69,418,000. Vanguard Group Inc. increased its position in shares of Aduro BioTech by 5.4% during the second quarter. Vanguard Group Inc. now owns 2,511,995 shares of the biotechnology company’s stock worth $28,637,000 after purchasing an additional 129,079 shares in the last quarter. State Street Corp grew its holdings in shares of Aduro BioTech by 8.3% during the second quarter. State Street Corp now owns 684,699 shares of the biotechnology company’s stock valued at $7,808,000 after buying an additional 52,597 shares during the last quarter. Baillie Gifford & Co. grew its holdings in shares of Aduro BioTech by 30.8% during the third quarter. Baillie Gifford & Co. now owns 553,090 shares of the biotechnology company’s stock valued at $5,891,000 after buying an additional 130,390 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in shares of Aduro BioTech by 15.1% during the second quarter. Northern Trust Corp now owns 453,115 shares of the biotechnology company’s stock valued at $5,166,000 after buying an additional 59,490 shares during the last quarter. Hedge funds and other institutional investors own 45.19% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Aduro BioTech (ADRO) Given a $10.00 Price Target by HC Wainwright Analysts” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://ledgergazette.com/2018/01/16/aduro-biotech-adro-given-a-10-00-price-target-by-hc-wainwright-analysts.html.
About Aduro BioTech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.